![Flavia Borellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Flavia Borellini
Directeur/Bestuurslid bij
REVOLUTION MEDICINES, INC.
Vermogen: 4 M $ op 31-05-2026
Profiel
Flavia Borellini currently serves as Independent Director at Cantargia AB since 2020, Independent Director at Revolution Medicines, Inc. since 2021, Director at Kartos Therapeutics, Inc. since 2018, and as a Member of Roche Group.
Former roles include Chief Executive Officer at Acerta Pharma BV from 2016 to 2019, Independent Director at Viracta Therapeutics, Inc. from 2021 to 2025, VP-Global Product & Portfolio Strategy at AstraZeneca PLC from 2018 to 2020, and Vice President-Program Leadership at Onyx Pharmaceuticals, Inc. from 2012 to 2013.
Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-06-2026 | 26.215 ( 0,01% ) | 4 M $ | 31-05-2026 |
Actieve functies van Flavia Borellini
| Bedrijven | Functie | Begin |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Directeur/Bestuurslid | 22-06-2021 |
| CANTARGIA AB | Directeur/Bestuurslid | 01-10-2020 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Directeur/Bestuurslid | 01-02-2018 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Eerdere bekende functies van Flavia Borellini
| Bedrijven | Functie | Einde |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur/Bestuurslid | 05-02-2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01-01-2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Algemeen Directeur | 01-02-2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01-10-2013 |
Opleiding van Flavia Borellini
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
42
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
